SGO Issues June 12, 2014
SGO plans practice summit on genetic testing and counseling
FDA sets morcellation hearing for July 10-11
Spillman elected to AMA Ethical and Judicial Affairs Council
Annual Meeting summary in June 2014 Gynecologic Oncology
SGO hires Director of Membership Engagement
House OK’s $20 million for DOD ovarian cancer research
Join SGO Surgeons Team for Race to End Women’s Cancer
On June 10, the American Medical Association (AMA) passed a resolution opposing any limitation on ordering of genetic testing based solely on physician specialty. SGO supported the resolution and plans to convene a practice summit to assess the landscape of the current practice of genetic testing and counseling and develop a model for future practice.
As the availability of and need for genetic information rapidly increases, SGO recognized the need to define which providers should provide counseling and perform testing. Ideally, patients should have access to specially trained genetic counselors for these services. However, there are instances in which these services are unavailable or are of limited availability, or timely treatment decisions rely on results of genetic tests linked to the diagnosis for which a physician is delivering medical care. In these instances, SGO believes it should be within the scope of the specialty-trained gynecologic oncologist to offer testing and counseling regarding genetic susceptibility to cancer.
SGO especially opposes restrictions on testing when results inform treatment decisions. The Society supports development of educational competencies to certify providers involved in cancer care to provide genetic counseling and testing. Representatives of professional societies, industry and insurance providers will be invited to the practice summit to ensure input from all stakeholders.
On July 10-11, the U.S. Food and Drug Administration (FDA) will host a public meeting of the Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee to discuss the safety of laparoscopic power morcellator devices as it pertains to their potential to disseminate and upstage a confined, but undetected (occult) uterine malignancy during laparoscopic hysterectomy or myomectomy.
The FDA is convening this committee to seek expert scientific and clinical opinion on the risks and benefits of these types of devices when used for these procedures, based on available scientific data. The committee will make recommendations regarding the appropriate use, premarket testing, labeling, and other risk mitigations (including the use of containment bags) for these devices.
On July 11, during the afternoon session, the committee will also be asked to discuss the regulatory classification of laparoscopic power morcellator devices when used to cut and extract tissue during gynecologic laparoscopic procedures and to assist FDA in determining the appropriate level of regulatory control necessary for this device type, including discussion of class II (special controls) or reclassification to class III (subject to premarket approval application [PMA]).
FDA is accepting public comments at http://www.regulations.gov through Aug. 11, 2014. Comments received on or before July 1, 2014, will be provided to the committee for their consideration. Comments received after July 1, 2014, will be taken into consideration by the Agency.
The American Medical Association announced earlier this week that Monique Spillman, MD, PhD, has been elected to serve a seven-year term on the AMA’s Council on Ethical and Judicial Affairs (CEJA).
Dr. Spillman is gynecologic oncologist and an Assistant Professor in the Department of Obstetrics and Gynecology at the University of Colorado School of Medicine in Aurora, CO.
CEJA is one of the three components of the Ethics Group of the AMA. The Council’s two main responsibilities are to maintain and update the 165-year-old Code of Medical Ethics, through its policy development function; and to promote adherence to the professional ethical standards set out in the Code through its judicial function.
The June 2014 issue of Gynecologic Oncology includes a “Summary of the 45th Annual Meeting on Women’s Cancers,” co-authored by Alexander B. Olawaiye, MD, from the University of Pittsburgh School of Medicine Magee-Womens Hospital in Pittsburgh, PA, and Carolyn Y. Muller, MD, University of New Mexico Cancer Center in Albuquerque, NM.
Kristin Belleson has joined the Chicago staff of the Society of Gynecologic Oncology as Director of Membership Engagement and Services. Belleson came to the SGO from ADA Business Resources, the for-profit subsidiary of the American Dental Association.
Belleson earned her Bachelor of Arts in Journalism and Mass Communications from the University of Iowa. She has been in an association environment—specifically focusing on marketing and membership—for the past 16 years.
As Affinity Marketing Manager within ADA Business Resources, Belleson focused on delivering member value to ADA members while continuing to grow non-dues revenue.
In her previous role at the ADA, she oversaw recruitment and retention initiatives, including coordinating and facilitating activities related to the ADA’s Membership Initiative, as well as providing hands-on membership recruitment and retention services to constituent and component membership committees and staff. Belleson also served as a consultant and trainer for many state and local dental societies throughout the country.
In addition to her work experience, she is active in her community and serves as a volunteer for ARFhouse Chicago Rescue Organization and PAWS, a no-kill animal shelter.
This week the House Appropriations Committee approved $20 million for the ovarian cancer research program at the Department of Defense. The FY2015 appropriations bill now goes to the entire House of Representatives for a vote. The Senate Appropriations Committee will begin its process later this summer and SGO’s government relations committee is continuing its grassroots efforts to maintain this level of funding with the Senate. To assist the committee with their efforts, contact Jill Rathbun.
Join team captain Linda Duska, MD, on the SGO Surgeons Team for the 2014 National Race to End Women’s Cancer, Sunday, Nov. 2, in Washington, D.C. Members who cannot attend can still register for the event or donate to support the movement.